Enhancing Quality of Informed Consent (EQUIC-DP) Developmental Phase
NCT ID: NCT00032552
Last Updated: 2010-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
632 participants
OBSERVATIONAL
1999-04-30
2006-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
EQUIC-CC: Enhancing Quality of Informed Consent - Customized Consent
NCT00032539
EQUIC-SM: Enhancing Quality of Informed Consent
NCT00032565
Empowering Veterans to Communicate With Healthcare Providers
NCT03529071
Research Participants Perceptions of Their Experience in Clinical Studies
NCT00729534
Evaluating the Quality of Different Methods of Obtaining Informed Consent
NCT00794729
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The parent-study staff will provide the research subject with privacy and place a call to the coordinating center. Staff (at the EQUIC coordinating center), who will be administering the Brief Informed Consent Evaluation Protocol (BICEP) to the research subject, will introduce themselves. Then, the subject will be interviewed using a BICEP structured assessment questionnaire of approximately 12-20 open ended questions, aimed at determining the success and validity of the informed consent process of the parent study. The results of the interviews will be used to fine-tune and adjust both the process of assessing informed consent in this manner as well as the questionnaire itself.
Primary Hypothesis: Enhancing the Quality of Informed Consent Development Phase (EQUIC-DP) is a pilot and instrument-development study that will be used as the base for a VA Cooperative Studies Program-wide initiative on informed consent, called EQUIC (Enhancing the Quality of Informed Consent). EQUIC-DP has as its primary aim the field testing and iterative improvement of a method for measuring the success of an informed consent encounter with a patient-subject.
Primary Outcomes: The quality of the informed consent process, as measured by the BICEP (Brief Informed Consent Evaluation Protocol). The BICEP also offers a method to certify informed consent in routine use.
Study Abstract: Practitioners of clinical trials have a responsibility to ensure that patients participation in research is informed and voluntary. This implies that we should continuously strive to improve the effectiveness of methods for informing prospective research volunteers about experimental studies, thereby enhancing the likelihood that their interests are respected. Innovations in informed consent should be tested in realistic contexts (i.e., in clinical trials) and when appropriate with randomization at the first opportunity. In this proposed project we take efforts to improve the quality of informed consent, based on experimentation with informed consent in ongoing clinical trials in the VA Cooperative Studies Program. The CSP is uniquely situated to serve as a testing ground for informed consent, not only because of concerns for enhancing consent for human experimentation, but also because of the centralized coordination of wide variety of clinical studies representing an extraordinary range of patient capacities and vulnerabilities. Moreover, such an effort is a special responsibility of the VA given the profound trust placed in the research enterprise by veterans.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
US Department of Veterans Affairs
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department of Veterans Affairs
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philip Lavori, PhD
Role: STUDY_CHAIR
VA Palo Alto Health Care System
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VA Medical Center, Birmingham
Birmingham, Alabama, United States
VA Palo Alto Health Care System
Palo Alto, California, United States
MIMA Century Research Assoc. (CSP #424) (DP)
Melbourne, Florida, United States
West Palm Beach VA Medical Center
West Palm Beach, Florida, United States
Edward Hines, Jr. VA Hospital
Hines, Illinois, United States
Richard Roudebush VA Medical Center, Indianapolis
Indianapolis, Indiana, United States
VA Ann Arbor Healthcare System
Ann Arbor, Michigan, United States
VA Medical Center, Minneapolis
Minneapolis, Minnesota, United States
Mayo Clinic Rochester (CSP #424) (DP)
Rochester, Minnesota, United States
VA Medical Center, St Louis
St Louis, Missouri, United States
VA Sierra Nevada Health Care System
Reno, Nevada, United States
VA Western New York Healthcare System at Buffalo
Buffalo, New York, United States
New York Harbor HCS
New York, New York, United States
VA Medical Center, Northport
Northport, New York, United States
VA Medical Center, Durham
Durham, North Carolina, United States
VA Medical Center, Philadelphia
Philadelphia, Pennsylvania, United States
Michael E. DeBakey VA Medical Center (152)
Houston, Texas, United States
VA Puget Sound Health Care System, Seattle
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
476DP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.